【承担过的主要科研项目】
主持承担国家自然科学基金项目4项、省部级/市局级等课题20余项，累计科研经费1000余万元。
[Major scientific research projects undertaken]
She has undertaken 4 National Natural Science Foundation projects and more than 20 projects of the provincial/ministerial level, with a total scientific research funding of more than 10 million yuan.
1. 国家自然基金委面上项目：基于多西他赛诱导三阴性乳腺癌全细胞抗原构建特异DC纳米疫苗的研究；82073387；55万；2021.01-2024.12；在研，主持。
2. 国家自然基金委地区科学基金项目：基于新药环巴胺的微环境响应自纳米化白蛋白-CD44双靶向PD-L1单抗纳米体系在三阴性乳腺癌中的作用及机制研究；81860547；34.8万；2019.01-2022.12；已结题，主持。
3. 国家自然基金委面上项目：热引导纳米化环巴胺靶向杀伤耐药性乳腺癌及作用机制；81573008；62.4 万；2016.01-2019.12；已结题，主持。
4. 国家自然青年基金委项目：基于纳米技术的联合生物治疗与化学药物治疗抗胰腺癌新策略―FAPα抗体－环巴胺－壳聚糖胶束；81201798；23万；2013.01-2015.12；已结题，主持。
5. 2023年上海市科委优秀学术带头人：PD-1重编程TNBC细胞膜抗原的特异双致敏DC疫苗逆转免疫耐受的研究；23XD1402800；40万2023.05-2026.04；在研。
6. 2022年上海市卫生健康委员会领军人才计划：肿瘤微环境影响乳腺癌抗PD-L1免疫治疗效果以及相互作用机制研究；2022LJ012；45万；2023.01-2025.12；在研。
7. 上海市浦东新区卫计委行业专项：NK 细胞联合 PD-1 抑制剂+白蛋白紫杉醇治疗晚期非小细胞肺癌的临床试验研究；PW2021E-05；100万；2021.12-2024.11；在研。
8. 上海市浦东新区“中央财政支持中医药传承创新发展示范试点项目” ：中西医协同旗舰科室（肿瘤科）；YC-2023-0403；40万；2023.10-2025.09；在研。
9. 上海市浦东新区卫生和计划生育委员会团队建设-重点专科：乳腺肿瘤；PWZzk2022-01；40万；2023.01—2026.12；在研。
10. 2024年度“‘浦东新区国家中医药发展综合改革试验区’建设项目”中西医结合高级人才；PDZY-2024-0701；20万；2024.06-2026.05；在研
【主要创新成果】
The major innovations
学术成果：
Academic achievements:
1. 申请人近期主要创新聚焦于纳米技术整合抗肿瘤研究、肿瘤免疫治疗研究。
2. 以第一作者及通讯作者发表SCI论文50余篇。其中结合跨学科纳米技术制备免疫药物递送系统增强抗PD-1/PD-L1疗效，有效抑制三阴性乳腺肿瘤生长，相关系列成果发表于《STTT》《ADV MATER》、《SMALL》等国际知名杂志，单篇最高影响因子达40.8。
3. 2019年度作为项目第一完成人，以“基于纳米材料抗肿瘤药物的设计合成与活性研究”及“纳米肿瘤靶向药物的构建及应用”项目分获上海市医学科技奖青年科技奖、上海市科技进步奖三等奖。2020年获上海市女医师协会第三届医树奖•临床医学科技创新奖三等奖。2023年以第三完成人获得中国妇幼健康科学技术奖自然科学一等奖。
4.2018年获得上海医学基金会“医苑新星”杰出青年医学人才，2022年获得上海市卫生健康领军人才、同医最美科技工作者，2023年获得上海市领军人才、上海市优秀学术带头人。
5. 申请实用型专利两项（申请号：201910791237.9；申请号：202311559070.6）。
临床成果：
Clinical achievement
1. 联合多家二甲医院、社区医院，完成浦东新区卫计委联合攻关项目“复发转移性乳腺癌个体化精准化诊疗模型建立”，通过结题验收，在多家医院进行推广应用。
2. 作为肿瘤疫苗研发临床顾问，与国内首个部署mRNA个体化肿瘤疫苗的斯微生物合作开展个体化mRNA肿瘤疫苗临床试验2项，逐步推进晚期及术后肿瘤患者的个体化免疫治疗试验进程，将有效推动国内mRNA肿瘤疫苗发展及肿瘤精准治疗，为个体化mRNA肿瘤疫苗制剂的生产应用及临床推广带来广阔前景。
3.2023年获得上海市巾帼建功标兵、上海医务工匠，第五届上海市仁心医师奖。
【论文发表】
以第一作者及通讯作者发表SCI论文50余篇（单篇最高影响因子: 40.8）。
Papers published
More than 50 SCI papers has been published as the first author and corresponding author (the highest impact factor of a single paper: 40.8).
1.Fan T, Zhang M, Yang J, Zhu Z, Cao W*, Dong C*. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023 Dec 13;8(1):450. doi: 10.1038/s41392-023-01674-3. (Q1, IF:40.8) (通讯作者)
2.Chen L, Zhou LL, Wang CH, Han Y, Lu YL, Liu J, Hu XC, Yao TM, Lin Y, Liang SJ, Shi S*, Dong CY*. Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers. 2019, 31, 1904997, doi:10.1002/adma. 201904997. (Q1, IF:32.086) (通讯作者)
3.Ye Q, Lin Y, Li R, Wang H*, Dong C*. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. Semin Cancer Biol. 2022 Nov;86(Pt 2):607-623. (Q1, IF:17.012)(通讯作者)
4.Zhao W, Hu X, Li W, Li R, Chen J, Zhou L, Qiang S, Wu W, Shi S*, Dong C*. M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy. Small. 2021 Apr;17(13):e2007051. (Q1, IF:15.153) (通讯作者)
5.Zhou L, Chen J, Li R, Wei L, Xiong H, Wang C, Chai K, Chen M, Zhu Z, Yao T, Lin Y, Dong C*, Shi S*. Metal-Polyphenol-Network Coated Prussian Blue Nanoparticles for Synergistic Ferroptosis and Apoptosis via Triggered GPX4 Inhibition and Concurrent In Situ Bleomycin Toxification. Small. 2021 Nov;17(47):e2103919. (Q1, IF:15.153) (共同通讯作者)
6.Hu XC, Li RH, Wu WJ, Fang K, Zhu ZN, Wang YX, Zhou LL, Chen MY, Dong CY*, and Shi S*. A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy. Journal of Controlled Release. 2022 Jun 20;348:660-671. (Q1, IF:11.467) (共同通讯作者)
7.Rao Y, Fan T, Zhou L, Fang K, Sun Y, Hu X, Wang A, Li R, Zhu Z, Dong C*, Shi S*. A positive self-amplified H2O2 and acidity circulation for boosting CDT-PTT-starvation therapy. J Control Release. 2023 Feb;354:701-712. (Q1, IF:11.467) (共同通讯作者)
8.Hu X, Li H, Li R, Qiang S, Chen M, Shi S*, Dong C*. A Phase-Change Mediated Intelligent Nanoplatform for Chemo/Photothermal/Photodynamic Therapy of Cancer. Adv Healthc Mater. 2023 Feb;12(5):e2202245. (Q1, IF:11.092)(通讯作者）
9.Sun Y, Fang K, Hu X, Yang J, Jiang Z, Feng L, Li R, Rao Y, Shi S*, Dong C*. NIR-light-controlled G-quadruplex hydrogel for synergistically enhancing photodynamic therapy via sustained delivery of metformin and catalase-like activity in breast cancer. Mater Today Bio. 2022 Aug 1;16:100375. (Q1, IF:10.761)(通讯作者)
10.Li R, Hu X, Shang F, Wu W, Zhang H, Wang Y, Pan J, Shi S*, Dong C*. Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals. Acta Biomater. 2022 Aug;148:218-229. (Q1, IF:10.633) (通讯作者)
11.Feng L, Chen M, Li R, Zhou L, Wang C, Ye P, Hu X, Yang J, Sun Y, Zhu Z, Fang K, Chai K, Shi S*, Dong C*. Biodegradable oxygen-producing manganese-chelated metal organic frameworks for tumor-targeted synergistic chemo/photothermal/ photodynamic therapy. Acta Biomater. 2022 Jan; 138:463-477. (Q1, IF:10.633) (通讯作者)
12.Zhu H, Dong C, Dong H, Ren T, Wen X, Su J, Li Y*. Cleavable PEGylation and hydrophobic histidylation of polylysine for siRNA delivery and tumor gene therapy. ACS Appl Mater Interfaces. 2014 Jul 9;6(13):10393-407.（Q1,IF:10.383）（并列第一作者）
13.Chen M, Yang J, Zhou L, Hu X, Wang C, Chai K, Li R, Feng L, Sun Y, Dong C*, Shi S*. Dual-Responsive and ROS-Augmented Nanoplatform for Chemo/Photodynamic/Chemodynamic Combination Therapy of Triple Negative Breast Cancer. ACS Appl Mater Interfaces. 2022 Jan 12;14(1):57-68. (Q1, IF:10.383) (共同通讯作者)
14.Qiang S, Hu X, Li R, Wu W, Fang K, Li H, Sun Y, Liang S, Zhao W, Wang M, Lin Y, Shi S*, Dong C*. CuS Nanoparticles-Loaded and Cisplatin Prodrug Conjugated Fe(III)-MOFs for MRI-Guided Combination of Chemotherapy and NIR-II Photothermal Therapy. ACS Appl Mater Interfaces. 2022 Aug 17;14(32):36503-36514.(Q1, IF:10.383)(通讯作者）
15.Yang J, Wang C, Shi S*, Dong C*. Nanotechnologies for enhancing cancer immunotherapy. Nano Res. 2020, doi.org/10.1007/s12274-020-2904-8. (Q1, IF: 10.269) (通讯作者)
16.Zhou L, Chen J, Sun Y, Chai K, Zhu Z, Wang C, Chen M, Han W, Hu X, Li R, Yao T, Li H, Dong C*, Shi S*. A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer. J Nanobiotechnology. 2021 Sep 4;19(1):261.(Q1, IF:10.2) (共同通讯作者)
17.Liu J, Hu X, Feng L, Lin Y, Liang S, Zhu Z, Shi S*, Dong C*. Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1α-dependent tumor hypoxia adaptation. J Nanobiotechnology. 2022 Apr 12;20(1):187.(Q1, IF: 10.2) (通讯作者)
18.Fang K, Sun Y, Yang J, Hu X, Chen M, Li R, Yang X, Fan T, Wu J, Tong X, Dong C*, Shi S*. A Dual Stimuli-Responsive Nanoplatform Loaded PtIV -Triptolide Prodrug for Achieving Synergistic Therapy toward Breast Cancer. Adv Healthc Mater. 2023 Jul 1:e2301328. （Q1, IF:10.0）（共同通讯作者）
19.Zhang D, Zhang Y, Zou X, Li M, Zhang H, Du Y, Wang J, Peng C, Dong C, Hou Z. CHST2-mediated sulfation of MECA79 antigens is critical for breast cancer cell migration and metastasis. Cell Death Dis. 2023 Apr 24;14(4):288. （Q1, IF:9.685）（共同通讯作者）
20.Liang S, Yang J, Lin Y, Li T, Zhao W, Zhao J, Dong C. Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review. Front Immunol. 2021 Jul 8;12:682262. (Q1,IF: 8.786) (通讯作者)
21.Chen JJ, Zhou LL, Wang CH, Sun YH, Lu YL, Hu XC, Chen MY, Chen L, Chai KK, Yao TM, Shi S*, Dong CY*. Multifunctional SN38-Conjugated Nanosystem for Defeating Myelosuppression and Diarrhea Induced by Irinotecan On Esophageal Cancer. Nanoscale. 2020, 12(41):21234-21247. (Q1,IF:8.307) (通讯作者)
22.Chen MY, Dong CY*, Shi S*, Nanoparticle-Mediated siRNA Delivery and Multifunctional Modification Strategies for Effective Cancer Therapy. Adv. Mater. Technol. 2021, 2001236. (IF: 7.848) (共同通讯作者)
23.Liang SJ, Sun ML, Lu YL, Shi S, Yang YT, Lin Y, Feng C, Liu J and Dong CY*. Cytokine-induced killer cells-assisted tumor-targeting delivery of Her-2 monoclonal antibody-conjugated gold nanostars with NIR photosensitizer for enhanced therapy of cancer. Journal of Materials Chemistry B, 2020, 8, 8368 – 8382. (Q1,IF:7.571) (通讯作者)
24.Feng C, Wang K, Lin Y, Song ZW, Lu YL, Liu J, Zhu DL, Li YY*, Dong CY*. Extracellular retention of a cyclopamine nanoformulation leveraging larger size and more negative charge for improved breast cancer treatment. J Mater Chem B, 2018, 6(12): 1834-1843 (Q1,IF: 7.571) (通讯作者)
25.Hu X, Zhao W, Li R, Chai K, Shang F, Shi S, Dong C. A cascade nanoplatform for the regulation of the tumor microenvironment and combined cancer therapy. Nanoscale. 2023 Oct 3.（Q1,IF:6.7）（通讯作者）
26.Ye P, Feng L, Shi S, Dong C. The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer. Cancers (Basel). 2022 Apr 23;14(9):2101.（Q1,IF:6.575）（通讯作者）
27.Hu XC, Lu YL, Zhao WR, Sun ML, Li RH, Feng L, Yao TM, Dong CY*, Shi S*. A PDA-DTC/Cu–MnO2 nanoplatform for MR imaging and multi-therapy for triple-negative breast cancer treatment. Chem. Commun. 2021, 57(34):4158-4161. (Q2, IF:6.065) (共同通讯作者)
28.Ye P, Guo Z, Zhang Y, Dong C*, Li M*. Surgery Plus Chemotherapy Versus Surgery Alone for Limited-Stage Small-Cell Lung Cancer: A Population-Based Survival Outcome Analysis. Front Oncol. 2021 May 17; 11:676598. (Q2, IF: 5.738) (通讯作者)
29.Hu X, Lu Y, Shi X, Yao T, Dong CY*, Shi S*. Integrating in situ formation of nanozyme with mesoporous polydopamine for combined chemo, photothermal and hypoxiaovercoming photodynamic therapy. Chem. Commun, 2019,55, 14785-14788 (Q2,IF: 6.164) (共同通讯作者)
30.Cai XJ, Dong CY, Dong HQ, Wang GM, Pauletti GM, Pan XJ, Shi DL. Effective gene delivery using stimulus-responsive catiomer designed with redox-sensitive disulfide and acid-labile imine linkers. Biomacromolecules. 2012;13:1024-34. （Q1,IF:6.978）（并列第一作者）
31.Ye P, Feng L, Zhang D, Li R, Wen Y, Tong X, Shi S, Dong C. Metformin Ameliorates D-Galactose-Induced Senescent Human Bone Marrow-Derived Mesenchymal Stem Cells by Enhancing Autophagy. Stem Cells Int. 2023 Mar 30;2023:1429642. doi: 10.1155/2023/1429642. （Q2,IF:5.131）(通讯作者)
32.Dong HQ, Dong CY, Ren TB, Li YY, Shi DL. Surface-engineered graphene-based nanomaterials for drug delivery. Journal of biomedical nanotechnology. 2014;10:2086-106. （Q3,IF:3.641）（并列第一作者）
33.Hu X, Lu Y, Zhou L, Chen L, Yao T, Liang S, Han J, Dong CY*, Shi S*. Post Syntheses Strategy to Integrate Porphyrinic Metal-Organic Frameworks with CuS NPs for Synergistic Enhanced Photo-therapy. J. Mater. Chem. B, 2020, DOI: 10.1039/C9TB02597A. (Q1,IF:7.571) (共同通讯作者)
34.Feng C, Chen L, Lu YL, Liu J, Liang SJ, Lin Y, Li YY*, Dong CY*. Programmable Ce6 delivery via cyclopamine based tumor microenvironment modulating nano-system for enhanced photodynamic therapy in breast cancer. Front. Chem., 2019; 7, 853 (Q2,IF: 5.545) (通讯作者)
35.Zhu DL, Zhang X, Lin Y, Liang SJ, Song ZW*, Dong CY*. MT1JP inhibits tumorigenesis and enhances cisplatin sensitivity of breast cancer cells through competitively binding to miR-24-3p. Am J Transl Res. 2019; 11(1): 245–256. (Q3,IF:3.940) (通讯作者)
36.Feng C, Zhu DL, Chen L, Lu YL, Liu J, Kim NY, Liang SJ, Zhang X, Lin Y, Ma YB*, Dong CY*. Targeted Delivery of Chlorin e6 via Redox Sensitive Diselenide-Containing Micelles for Improved Photodynamic Therapy in Cluster of Differentiation 44-Overexpressing Breast Cancer. Front Pharmacol. 2019; 10: 369. (Q1,IF: 5.988) (通讯作者)
37.Lu YL, Ma YB, Feng C, Zhu DL, Liu J, Chen L, Liang SJ*, Dong CY*. Co-delivery of Cyclopamine and Doxorubicin Mediated by Bovine Serum Albumin Nanoparticles Reverses Doxorubicin Resistance in Breast Cancer by Down-regulating P-glycoprotein Expression. Journal of Cancer. 2019; 10(10): 2357–2368. (Q2,IF: 4.478) (通讯作者)
38.Liu J, Song ZW, Feng C, Lu YL, Zhou Y, Lin Y, Dong CY*. The long non-coding RNA SUMO1P3 facilitates breast cancer progression by negatively regulating miR-320a. Am J Transl Res, 2017; 9(12): 5594–5602. (Q3,IF:3.940) (通讯作者)
39.Song ZW, Feng C, Lu YL, Gao Y, Lin Y, Dong CY*. Overexpression and biological function of MEF2D in human pancreatic cancer. Am J Transl Res. 2017; 9(11):4836-4847. (Q3,IF:3.940) (通讯作者)
40.Song Z, Zhang X, Ye XJ, Feng C, Yang G, Lu YL, Lin Y, Dong CY*. High Expression of Stromal Cell-Derived Factor 1 (SDF-1) and NF-kappaB Predicts Poor Prognosis in Cervical Cancer. Medical science monitor: international medical journal of experimental and clinical research. 2017;23:151-7. (Q3,IF:3.386) (通讯作者)
41.Song Z, Lu YL, Zhang X, Wang HP, Han JY, Dong CY*. Novel curcumin-loaded human serum albumin nanoparticles surface functionalized with folate: characterization and in vitro/vivo evaluation. Drug design, development and therapy. 2016;10:2643-9. (Q2,IF:4.319) (通讯作者)
42.Song Z, Shao C, Feng C, Lu YL, Gao Y, Dong CY*. Association of glutathione S-transferase T1, M1, and P1 polymorphisms in the breast cancer risk: a meta-analysis. Ther Clin Risk Manag. 2016;12:763-9. (Q3,IF:2.755) (通讯作者)
43.Song ZW, Gao Y, Ye XJ, Zhang X, Yang G, Feng C, Lu YL； Dong CY*. Increased expression of PDGF-BB predicts metastasis and poor prognosis in ovarian cancer patients. International journal of clinical and experimental pathology. 2016;9:5487-92. (IF:1.396) (通讯作者)
44.Song ZW, Lin Y, Ye XJ, Feng C, Lu YL, Yang G, Dong CY*. Expression of IL-1 alpha and IL-6 is Associated with Progression and Prognosis of Human Cervical Cancer. Med Sci Monitor. 2016;22:4475-81. (Q3,IF:3.386) (通讯作者)
45.Song ZW, Lin Y, Zhang X, Ye XJ, Yang G, Feng C, Lu YL, Dong CY*. Expression of FAP is correlated with clinical prognosis in ovarian cancer patients. International journal of clinical and experimental medicine. 2016;9:11379-84. (IF:0.833) (通讯作者)
46.Feng C, Li XY, Zhang XM, Zhang X, Gao Y, Dong CY*. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer. Drug design, development and therapy. 2015;9:4613-20. (Q2,IF: 4.319) (通讯作者)
47.Li YY, Chen YQ, Dong HQ, Dong CY*. Supramolecular, prodrug-based micelles with enzyme-regulated release behavior for controlled drug delivery. Medchemcomm. 2015;6:1874-81. (IF:2.342) (通讯作者)
48.Dong HQ, Dong CY, Xia WJ, Li YY, Ren TB. Self-assembled, redox-sensitive, H-shaped pegylated methotrexate conjugates with high drug-carrying capability for intracellular drug delivery. Medchemcomm. 2014;5:147-52 （IF:2.342）（并列第一作者）
49.Chu M, Dong CY, Zhu HY, Cai XJ, Dong HQ, Ren TB, Li YY. Self-assembled, redox-sensitive, H-shaped pegylated methotrexate conjugates with high drug-carrying capability for intracellular drug delivery. Polym Chem-Uk. 2013;4:2528-39. （IF:4.927）（并列第一作者）
50.Li DL, Dong CY*, Gao Y. A simple and sensitive HPLC-UV method for the determination of swainsonine in rat plasma and its application in a pharmacokinetic study. Arzneimittel-Forschung. 2012;62:209-12. (IF:0.693) (通讯作者)
51.Dong HQ, Dong CY, Feng Y, Ren TB, Zhang ZH, Li L, Li YY. Engineering of peglayted camptothecin into core-shell nanomicelles for improving solubility, stability and combination delivery. Medchemcomm. 2012;3:1555-1561.（IF: 2.342）（并列第一作者）
